Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453374 | 1.00 | TACR3 (0.47) | TACR3POLBKDM4EALDH1A1AOC3 | |
| SCHEMBL17956754 | 0.95 | TACR3 (0.46) | TACR3POLBKDM4EALDH1A1AOC3 | |
| SCHEMBL5458502 | 0.90 | AOC3 (0.47) | TACR3POLBKDM4EALDH1A1AOC3 | |
| SCHEMBL5465120 | 0.84 | FAAH (0.43) | ALDH1A1MEN1KMT2A | |
| SCHEMBL1955589 | 0.84 | POLB (0.54) | TACR3POLBKDM4EALDH1A1CNR2 | |
| SCHEMBL11239095 | 0.83 | NPC1 (0.54) | TACR3KDM4EALDH1A1NPC1MEN1 | |
| SCHEMBL28072056 | 0.81 | ROCK1 (0.47) | TACR3ALDH1A1NPC1 | |
| SCHEMBL28072058 | 0.81 | ROCK1 (0.47) | TACR3ALDH1A1NPC1 | |
| SCHEMBL894067 | 0.80 | POLB (0.56) | TACR3POLBKDM4EALDH1A1CNR2 | |
| SCHEMBL15093398 | 0.80 | POLB (0.56) | TACR3POLBKDM4EALDH1A1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007090134-A2 | USE OF VANILLOID RECEPTOR-1 ANTAGONISTS FOR THE PREVENTION AND TREATMENT OF GLAUCOMA | ALCON MANUFACTURING, LTD. (US) | 2007-08-09 | — | — | WO | claimed |
| US-8420679-B2 | Aminothiazole derivatives and their use as CRF receptor ligands | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20070281919-A1 | Aminothiazole Derivatives And Their Use As CRF Receptor Ligands | SANOFI-AVENTIS (FR) | 2007-12-06 | — | — | US | disclosed |
| CN-1167692-C | Aminothiazole derivatives and their use as CRF receptor ligands | ʥŵ��-�ϳ�ʵ���ҹ�˾ | 2004-09-22 | — | — | CN | disclosed |
| EP-1200419-B1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI SYNTHELABO (FR) | 2004-04-14 | — | — | EP | disclosed |
| US-6586456-B1 | Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide | SANOFI-SYNTHELABO (FR) | 2003-07-01 | — | — | US | disclosed |
| CN-1370154-A | Aminothiazole derivatives and their use as CRF receptor ligands | SANOFI SYNTHELABO (FR) | 2002-09-18 | — | — | CN | disclosed |
| EP-1200419-A1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001005776-A1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281919-A1 | Aminothiazole Derivatives And Their Use As CRF Receptor Ligands | CRH, CRHR1, CRHR2 | TACR3 210/4885POLB 4782/4885KDM4E 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.